HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy [PDF]
BACKGROUND: Androgen deprivation therapy (ADT) worsens glycaemic control and cardiovascular outcomes. The prognostic value of visit-to-visit HbA1c variability (VVHV) has been unexplored in prostate cancer (PCa) patients receiving ADT.
Tse, Gary +9 more
core +3 more sources
Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer [PDF]
Objective To examine the role of androgen receptor (AR) gene amplification and aneusomy of the X chromosome in the development of antiandrogen-resistant prostate cancer.
Watters, A.D. +5 more
core +1 more source
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]
Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Edwards, J., Bartlett, J.M.S.
core +1 more source
Bad expression influences time to androgen escape in prostate cancer [PDF]
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Teo, K. +4 more
core +1 more source
OBJECTIVE: : At the time of diagnosis, approximately 16.5% of prostate cancer patients are metastatic. The main framework of metastatic prostate cancer treatment is androgen deprivation therapy, which is performed surgically or medically. The aim of this
Kisa, Erdem +22 more
core +1 more source
Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy [PDF]
Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).1 However, it is associated with increased cardiovascular risks, including elevated risks of ...
Tse, G.
core
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways [PDF]
Prostate cancer is the second leading cause of cancer related deaths in men from the western world. Treatment of prostate cancer has relied on androgen deprivation therapy for the past 50 years.
J Edwards +3 more
core +1 more source
A 3D in vitro model reflecting the androgen deprivation state in prostate cancer bone metastasis [PDF]
In castrate-resistant prostate\ud cancer (CRPC), the prevailing organ for\ud metastasis is bone, where the survival of\ud cancer cells is regulated by the permissive\ud metastatic niche offered by the bone marrow.\ud The tumour microenvironment and\ud ...
Loessner, Daniela +3 more
core +3 more sources
From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells [PDF]
Elucidating the role of androgen deprivation in the transition from androgen-dependence to independence may enable the development of more specific therapeutic strategies against prostate cancer. Our previous in vitro model was employed to further assess
Mendes, Desiree E +2 more
core +1 more source
Denosumab in men receiving androgen-deprivation therapy for prostate cancer [PDF]
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Szwedowski, M. +25 more
core +1 more source

